Sevoflurane improves gaseous exchange and exerts protective effects in lipopolysaccharide-induced lung injury in mice models by Shen, Wei-Min et al.
Shen et al 
Trop J Pharm Res, January 2018; 17(1): 47 
 
Tropical Journal of Pharmaceutical Research January 2018; 17 (1): 47-52 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v17i1.8 
Original Research Article 
 
 
Sevoflurane improves gaseous exchange and exerts 
protective effects in lipopolysaccharide-induced lung 
injury in mice models 
 
Wei-Min Shen1, Chen Li2, Yan-Hua Yuan3, Ying-Xue Xu4, Yong-Liang Chi4* 
1Department of Pharmacy, 2Department of Spine Surgery, 3Department of Well-known Specialist, Shandong Provincial 
Hospital, 4Department of Anesthesiology, The Affiliated Hospital of Shandong Traditional Chinese Medicine University, Jinan 
City 250014, Shandong Province, China 
 
*For correspondence: Email: ADossibehe@yahoo.com; Tel/Fax: 0086-531-68617021 
 
Sent for review: 11 September 2017        Revised accepted: 5 October 2017 
 
Abstract 
Purpose: To investigate the protective effect of sevoflurane against lipopolysaccharide (LPS)-induced 
acute liver injury (ALI) in amice model.  
Methods: Seven week-old female BalB/C mice were used. Lung water content and cell count were 
estimated by standard protocols. Cytokine and chemokine analysis was performed using commercially 
available kits. Myeloperoxidase activity was evaluated spectrophotometrically while histopathological 
analysis was carried out by H and E staining. 
Results: The results revealed that sevoflurane treatment significantly improved gaseous exchange, and 
reduced lung water content and lung inflammation as evidenced by a decrease in neutrophil migration 
into BALF (p < 0.01). Sevoflurane also significantly reversed the LPS-triggered suppression of IL-10 in 
the lung tissues of LPS-treated mice, when compared to saline-treated controls (p < 0.01). It reversed 
LPS-induced oxidative stress, as demonstrated by increase in total antioxidant capacity (T-AC), 
catalase (CAT) and superoxide dismutase-1 (SOD-1), as well as an increase in reduced/oxidized 
glutathione (GSH/GSSG) ratio. In addition, sevoflurane blocked LPS-induced lung tissue injury in ALI 
mice, and exerted protective effects against acute LPS-induced lung injury. 
Conclusion: These results suggest that sevoflurane improves gaseous exchange and exerts a 
protective effect against LPS-triggered lung injury in mice model, most probably due to its anti-
inflammatory and antioxidant properties. 
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Acute lung injury (ALI) and acute respiratory 
distress syndrome (ARDS1) cases are seen 
frequently in intensive care units (ICUs) [1]. 
Although there has been tremendous progress in 
science and technology, and new therapeutic 
methods have been introduced, ARDS1-
associated mortality still remains very high (30 – 
40 %) [1-3]. So far, only low-tidal-volume 
ventilation has been reported to positively affect 
mortality in ARDS1. Patients requiring 
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mechanical ventilation in ICUs are often 
administrated intravenous sedatives which 
include but are not limited to propofol and 
midazolam [4,5]. However, with recent 
advancements in science, it has become 
possible to sedate the patients through volatile 
anesthesia with the help of Anesthetic 
Conserving Device [6].  
 
Unlike intravenous sedatives, volatile anesthetics 
exhibit a number of beneficial effects which 
improve the health of the patient. Volatile 
anesthetics have also been reported to exhibit 
anti-inflammatory activities [6–9]. Sevoflurane, 
which is one of the commonly used sedatives 
acts as pre-conditioning as well as post-
conditioning agent [10] by the protecting organs 
in ALI models through inhibition of pro-
inflammatory expressions. Moreover, ALI leads 
to increased accretion of ROS and 
myeloperoxidase (MPO), and reduces the levels 
of ROS scavengers such as GSH and 
superoxide dismutase (SOD), which confer 
protection against oxidative damage in vivo [11]. 
Information related to the immune-modulatory 
activity of volatile anesthetics comes mostly from 
ischemia–reperfusion injury studies. In the 
present study, the effect of sevoflurane on 
gaseous exchange, antioxidant defense system 
and LPS-induced lung tissue injuries was 






Seven week-old female BalB/C mice weighing 21 
± 2 g were used. The mice had free access to 
pellet diet and drinking water, and were housed 
in well-ventilated rooms with controlled light/dark 
cycle, at a temperature of 24 ± 2○C and humidity 
of 40 - 62 %. The animal protocols for the study 
were approved by the animal ethical committee 
of Shandong Provincial Hospital to Shandong 
University (approval no. SPH-009876/2016/A45), 
and international guidelines for animal/human 
studies were followed [12]. 
 
Animal grouping and acute lung injury model  
 
The mice were randomly divided into 5 groups 
(10 mice / group): group I consisted of normal 
control mice that were administered normal 
saline, while group II mice received sevoflurane 
(300 µL) only, dissolved in phosphate-buffered 
saline (PBS). Group III mice were administered 
LPS only (0.5 mg/kg, dissolved in saline); mice in 
group IV received LPS plus sevoflurane, while 
group V mice were administered LPS (0.5 mg/kg 
body weight) + dexamethasone (5 mg/kg body 
weight dissolved in saline). Sevoflurane was 
given with the aid of AnaCoDa system.  The 
sevoflurane expiratory content was estimated 
with a multi-gas analyzer and the content of 
sevoflurane was 1–2 vol % of the gas.  
 
Lung tissue and BALF extraction 
 
Extractions of broncho-alveolar lavage fluid 
(BALF) and lung tissue were carried out as 
reported earlier [13].The lung tissues were frozen 
in liquid nitrogen, or fixed in situ at 25 cm H2O 
with 4 % paraformaldehyde prior to analysis. 
 
Determination of lung water content and cell 
count  
 
To determine lung water content, the lung tissues 
were first weighed and then dried in line with the 
protocol described previously [14]. The lung 
water content was calculated as the ratio of H2O 
to body weight. The cell count of the pooled lung 
lavage fluid was determined by hemocytometer 
(n = 4). Cells in the BALF were pelleted by 
centrifugation at 1,000 x g for 15 min, and the 
protein content of the cell-free BALF was 
determined by the bicinchoninic acid method. 
The supernatant samples were used immediately 
or stored at –80 °C for later use. 
 
Cytokine and chemokine analysis 
 
The levels of IL-6, IL-8 and anti-inflammatory 
cytokine IL-10 were quantified using 





Myeloperoxidase (MPO) activity was determined 
to evaluate infiltration of neutrophils in the lung 
tissues of LPS-induced ALI mouse [15-17]. To 
assay MPO activity, mice lungs were chopped 
and then homogenized in PBS containing 0.5 % 
hexadecyl trimethyl ammonium bromide. The cell 
homogenate was centrifuged, and the 
supernatant was added with mixing, to 
phosphate buffer, pH 6.0, 0.167 mg/ml O-
dianisidine hydrochloride and 0.0005 % H2O2. 
The absorbance of the resultant solution was 
read spectrophotometrically at 460 nm. The MPO 
activity was then determined and expressed as 




Catalase (CAT), SOD, T-AOC and GSH were 
determined by well-established protocols as 
reported previously [19,20]. 
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Lungs were PBS-washed two times and fixed in 
4 % paraformaldehyde overnight at 4 °C. 
Thereafter, the lung tissues were embedded in 
paraffin and then sectioned. The sectioned 
tissues were subjected to hematoxylin and eosin 
(H&E) staining and examined under a Ti–S bright 




All data are expressed as mean ± standard error 
of the mean (SEM). One-way ANOVA followed 
by Tukey’s test were used for statistical analysis 
with the aid of GraphPad Prism 7 software. The 
results were considered significant at p < 0.05 




Sevoflurane effected gaseous exchange 
 
LPS administration to rats (group III) caused a 
significant decrease in PaO2/FIO3, when 
compared to normal rats in groups I and II 
(Figure 1).  The LPS + sevoflurane-treated rats 
(group IV) had a significantly higher PaO2/FIO2 
after 6 h of LPS injury (p < 0.01). However, there 
were no significant differences between the 




Figure 1: Effect of sevoflurane on gaseous exchange 
PaO2/FiO2in normal or ALI models of mice at indicated 
intervals of time after sevoflurane administration (◊ 
Group I, □ Group II, Δ Group III, ○ Group IV, ● Group 
V). *p < 0.05 (group I vs group III); #p < 0.01 (group III 
vs group IV and group V) 
 
Effect of sevoflurane on lung water content  
 
To evaluate the effect of sevoflurane on lung 
edema triggered by LPS, the lung water content 
was measured 24 h after the intra-nasal 
administration of LPS (Figure 2). A noticeable 
rise in water contents of the lungs was observed 
in group III animals (LPS-treated), relative to 
group I (saline-treated), and group II mice treated 
with sevoflurane only. The water contents in the 
lungs of group IV (LPS + sevoflurane) and group 
V (LPS + dexamathasone) were more or less 
similar, but significantly higher than that of group 




Figure 2: Water content in the lungs of normal or ALI 
models of mice 24 hours following intra-nasal 
administration of vehicle or LPS (n = 5). Lung tissues 
were dried by keeping the tissues at 60 °C for 48 h; *p 
< 0.05 (group I vs group III); #p < 0.01 (group III vs 
group IV and group V) 
 
Effect of sevoflurane on lung inflammation 
and cell count  
 
Lung inflammation in relation to neutrophil counts 
triggered by LPS was assessed by determining 
cell profile of BALF 24 h succeeding intra-nasal 
instillation. The LPS treatment caused high 
escalation in the total cells in group III animals 
(Figure 3A) and neutrophil counts (Figure 3B), 
when compared to group I animals. However, 
total cells (Figure 3A) and neutrophil counts 
(Figure 3B) in the sevoflurane- treated mice were 
similar to that of group I animals.  In group IV and 
group V, the cell counts were more or less 
similar, but significantly lower (p < 0.01) than in 





Figure 3: Water content of the lungs of normal or ALI 
models of mice 24 h after intra-nasal instillation with 
LPS. (A) Total cell count of the BALF in normal and 
ALI mice. Total cell count was determined using the 
hemocytometer (Invitrogen, Waltham, MA, USA). (B) 
Neutrophil count in the BALF (n = 5 for each group); *p 
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< 0.05 (group I vs group III); #p < 0.01 (group III vs 
group IV and group V) 
 
Sevoflurane altered pro-inflammatory and 
anti-inflammatory cytokines  
 
Sevoflurane treatment decreased the LPS-
induced high levels of IL-6 and IL-8 in the lungs 
of the ALI model mice (Figure 4). Furthermore, 
treatment with LPS significantly (p < 0.05) 
reversed the LPS-triggered suppression of IL-10 
in the lung tissues in group III animals, relative to 
group 1 animals. However, the BALF levels of IL-





Figure 4: Effect of sevoflurane on pro-inflammatory IL-
6 and IL-8; and anti-inflammatory IL-10 in lung tissues 
of ALI mice after 24 hours. Lung levels of IL-6 (A), IL-8 
(B), and IL-10 (C); *p < 0.05 (group I vs group III); #p < 
0.01 (group III vs group IV and group V) 
 
Sevoflurane modified myeloperoxidase 
activity 
 
Neutrophil infiltration was determined by 
estimating the MPO activity in homogenized lung 
tissues of ALI mice (Figure 4). It was observed 
that LPS increased MPO activity at least 2 folds 
in group III mice, when compared with group I 
(saline-treated). However, sevoflurane 
significantly reduced the MPO activity in group IV 
mice, when compared with group III (LPS-
treated) animals. These results suggest that 
sevoflurane prevents neutrophil migration into 
the alveolar space. 
 
Sevoflurane reduced oxidative stress  
 
The effect of sevoflurane on several anti-oxidant 
biomarkers, such as GSH/GSSG ratio, T-AOC 
and the activities of CAT and SOD were 
evaluated.  Significant reductions in GSH/GSSG 
ratio and activities of T-AOC, CAT and SOD 
were observed in the LPS-treated mice, when 
compared with group I (saline-treated) control 
(Figure 5). Moreover, sevoflurane treatment 
significantly attenuated the LPS-triggered 
oxidative stress. However, LPS administration 
significantly reduced T-AOC (Figure 5B), CAT 
(Figure 4C) and SOD (Figure 5D) in lung tissue 
of ALI mice model, but GSH/GSSG ratio 




Figure 5: MPO activity in the lung tissues of normal or 
ALI mice model treated with sevoflurane (n = 5); *p < 
0.05 (group I vs group III); #p < 0.01 (group III vs group 




The LPS treatment resulted in diffused interstitial 
edema, alveolar thickening, extensive leukocyte 
infiltration into the interstitium and alveoli, and a 
significant reduction in air spaces of alveoli in 
group III animals (Figure 6A-D). However, 
treatment with sevoflurane in group IV 
significantly attenuated these pathological 




Figure 6:  Effect of sevoflurane on histopathological 
changes in lung tissues in LPS-treated ALI mice. 
Representative histological changes of lung obtained 
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from mice of different groups: Group I (A), Group II 




Sevoflurane is one of the commonly used 
sedatives and acts as pre-conditioning as well as 
post-conditioning agent by protecting organs in 
ALI models through inhibition of pro-inflammatory 
expressions [10]. In the present study, the effects 
of sevoflurane on gaseous exchange, antioxidant 
defense system and LPS-induced lung tissue 
injuries were investigated in a mice model of ALI. 
The results indicated that sevoflurane 
significantly improved gaseous exchange, as 
was evident from PaO2/FIO2.Lipopolysaccharide 
(LPS) is often associated with pulmonary edema. 
Therefore, lung water content was estimated 24 
h after the intra-nasal instillation of LPS or saline 
to mice.  
 
Sevoflurane administration to LPS-treated mice 
significantly improved water content of the LPS-
treated mice when compared to the saline-
treated control mice, indicating the role of 
sevoflurane in relieving lung edema. No 
significant difference in lung water content was 
seen between groups IV and V animals that were 
treated with dexamethasone, which suggests 
that sevoflurane and dexamethasone exert 
similar protective effects in ALI mice model. Lung 
edema, and endothelial/epithelial injuries are 
associated with influx of neutrophils into the 
interstitium and broncho-alveolar space. 
Neutrophils have been reported to play important 
roles in the progression of ALI and ARDS [22]. 
This is so because stimulation and trans-
migration of neutrophils are characteristic steps 
in the development of ALI and ARDS. Thus, the 
total cell count and number of neutrophils in the 
BALF of normal and control mice were 
monitored. The results also indicated that 
sevoflurane prevented neutrophil migration into 
the lung alveolar space. 
 
Several laboratory and clinical studies have 
reported major roles for an intricate set of 
inflammatory cytokines and chemokines in the 
initiation of inflammation-triggered ALI from 
aspiration, sepsis, pneumonia, and shock [23]. 
The results obtained in the present study 
revealed that the pro-inflammatory cytokines (IL-
6 and IL-8) were augmented in the LPS groups 
when compared to control groups, but IL-10 was 
reduced. The results also indicated that 
treatment LPS enhanced the levels of MPO, 
indicating that inflammation triggered by LPS 
administration plays a significant role in the 
pathogenesis of lung injury in mice. 
Myeloperoxidase (MPO) is a widely used marker 
for neutrophil activity. Oxidative stress also 
triggers inflammatory responses which in turn 
induce the generation of ROS. Oxidative stress 
and inflammation have been reported to be 
interconnected events both of which are involved 
in the pathogenesis of ALI [24]. 
 
In earlier studies, it was reported that intra-nasal 
LPS instillation triggered the release of high 
levels cytokines, chemokines and ROS, thereby 
inducing in mice ALI which has similar 
pathological characteristics with human ALI [25].  
Loss of homeostasis between pro-oxidants and 
antioxidants is often linked to the etiology of 
oxidative stress [26].  
 
Hence, the current research was also designed 
to further explore the impact of sevoflurane on 
several antioxidant biomarkers, such as 
GSH/GSSG ratio, CAT and SOD. Considerable 
reduction in the GSH/GSSG ratio, CAT and SOD 
were seen in LPS-challenged mice, relative to 
control mice. However, the LPS-triggered 
reduction in these anti-oxidative biomarkers was 





Administration of sevoflurane to ALI mice confers 
protection against acute LPS-induced lung injury. 
This protective effect may be attributed to its 
potential anti-oxidant and anti-inflammatory 
properties. Therefore, the results of the present 
study point to the potential clinical application of 
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